Allergy Immunity Shots: Why It's Tolerance, Not Antibody Immunity
'Allergy immunity shots' is an informal name for subcutaneous immunotherapy (SCIT) — a 3-to-5-year course governed by Cox 2011 PP3. Clinically, SCIT builds allergen-specific tolerance (Treg cells, IgG4 blocking antibodies) rather than vaccine-style antibody immunity. Durham 1999 NEJM documented 4 years of post-treatment remission after 3 years of grass SCIT.
7 peer-reviewed sources
'Allergy immunity shots' = SCIT (subcutaneous immunotherapy). The mechanism is allergen-specific tolerance induction via regulatory T cells and IgG4 blocking antibodies — the immune opposite of vaccine-induced antibody immunity. 3-to-5-year course per Cox 2011. Functionally feels like 'immunity' (fewer symptoms on exposure) but mechanism is tolerance, not antibody memory.
Allergy Immunity Shots: The Right Intent, The Wrong Word
'Allergy immunity shots' uses an informal 'build up immunity' framing. The patient intent maps cleanly to subcutaneous immunotherapy (SCIT) per the AAAAI/ACAAI/JCAAI Practice Parameter Third Update (Cox L et al, J Allergy Clin Immunol 2011;127[1 Suppl]:S1-S55, DOI 10.1016/j.jaci.2010.09.034) — but the precise clinical term is 'tolerance' or 'desensitization,' not 'immunity.'
This terminology distinction matters because the mechanism is the opposite of vaccine-induced immunity. Infectious-disease vaccines (MMR, DTaP, COVID-19) teach the immune system to attack a pathogen via high-affinity IgG antibodies and T cell memory. Allergen immunotherapy teaches the immune system to NOT react to harmless environmental proteins via regulatory T cell (Treg) induction, IL-10 and TGF-β production, and IgG4 'blocking' antibodies that compete with IgE for allergen binding. The endpoint feels like immunity to the patient (fewer or no symptoms on subsequent allergen exposure), which is why the word sticks — but immunologically it's tolerance, not immunity.
Curex pairs at-home IgE testing with allergist review to identify the specific allergens driving symptoms — the diagnostic prerequisite for any immunotherapy course aimed at building allergen-specific tolerance under Cox 2011.
The practical course: ~26-28 weekly build-up injections + ~13 early-maintenance visits in Year 1 (~39 total visits), followed by maintenance every 2-4 weeks for 3-5 total years per Cox 2011 PP3. Durham SR et al (N Engl J Med 1999;341:468-475, DOI 10.1056/NEJM199908123410702) showed that 3 years of grass SCIT produced 4 years of sustained post-treatment remission — the closest evidence we have to durable 'immunity-like' protection from allergens.
Cochrane Calderón 2007 (DOI 10.1002/14651858.CD001936.pub2) meta-analysis of 51 RCTs (n=2,871) found symptom SMD −0.73 and medication SMD −0.57 versus placebo. Tkacz 2021 (Curr Med Res Opin 2021;37[6]:957-965, DOI 10.1080/03007995.2021.1903848) MarketScan analysis of 103,207 real-world patients found 43.9% reached maintenance — durability hinges on completing the full course.
Cox/Murphey/Hankin 2020 (Immunol Allergy Clin North Am 2020;40[1]:69-85, PMID 31761122) concluded that SCIT is the only disease-modifying allergy therapy — biologics (Xolair, Dupixent) and antihistamines control symptoms but do not build the durable tolerance that allergen immunotherapy produces.
'Allergy immunity shots' = SCIT. Mechanism is Treg tolerance, not antibody immunity. 3-to-5-year course. Durable post-treatment remission requires completing the full course.
Treg Tolerance vs. Antibody Immunity: The Mechanism Distinction
The mechanism by which 'allergy immunity shots' (SCIT) produces its effect is the immune opposite of the mechanism by which infectious-disease vaccines produce protection.
Antigen (attenuated virus, protein subunit, or mRNA-encoded protein) is presented to naive B cells and T cells. Germinal center reactions produce high-affinity IgG antibodies and long-lived plasma cells. Subsequent pathogen exposure is neutralized by pre-formed antibodies before symptomatic infection develops. One or two doses establish decades-long memory.
Escalating doses of allergen extract are administered subcutaneously into the upper outer arm. Repeated sub-symptomatic antigen exposure in the presence of regulatory dendritic cells shifts allergen-specific T cell responses away from Th2 (IL-4, IL-5, IL-13) toward Treg (IL-10, TGF-β). Outcomes: induction of allergen-specific Treg cells that suppress mast-cell and eosinophil activation; production of IgG4 'blocking' antibodies that compete with IgE for the same allergen; reduction in mast-cell mediator release on re-exposure. This is tolerance induction, not immunity induction. The body learns to NOT react, rather than learning to destroy a threat.
Treg tolerance is cumulative — it builds with each injection and requires consistent antigen re-exposure to maintain. Unlike antibody memory that persists for decades from a few doses, Treg tolerance requires 3-5 years of regular maintenance dosing to become durable post-treatment per Cox 2011 PP3. Tkacz 2021 (DOI 10.1080/03007995.2021.1903848) MarketScan analysis of 103,207 patients found only 43.9% reached maintenance, and 23.9% never returned after their first injection — adherence is the single largest predictor of failure.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Course Length: Why It's Years, Not Months
Per Cox 2011 PP3, SCIT follows a 3-to-5-year course divided into build-up and maintenance phases. The duration is set by the time required for Treg tolerance to become durable.
Weekly subcutaneous injections at escalating concentrations from 1:10,000 dilute to maintenance vial. Each visit includes a mandatory 30-minute observation period per AAAAI position statement. ~26-28 visits total in this phase.
Once maintenance dose is reached, injections continue every 2-4 weeks. Per Cox 2011, the full course is 3-5 years total. Year 1 visits total ~39 (build-up + early maintenance). Years 2-5 visits ~13-26 per year.
Durham 1999 NEJM (DOI 10.1056/NEJM199908123410702) documented 4 years of sustained remission after 3 years of grass SCIT. This durability is the closest analog to vaccine-style 'immunity' but is produced by completed tolerance induction, not antibody memory. Some real-world cohorts show 7-12+ years of durability.
Does Allergen Tolerance Induction Work?
Yes — Cochrane meta-analyses and landmark RCTs document moderate-to-large effect sizes across multiple allergen categories. Post-treatment durability is what distinguishes SCIT from symptom-suppression drugs.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youTolerance vs. Symptom Suppression vs. Immune Blockade
Allergy immunity shots (SCIT) build durable tolerance. Antihistamines and intranasal steroids suppress symptoms but don't modify the underlying disease. Biologics (Xolair, Dupixent) modulate immune-mediated disease but don't induce allergen-specific tolerance.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
SCIT (allergy immunity shots) | |||||
SLIT drops / tablets | |||||
Antihistamines / intranasal steroids | |||||
Xolair (omalizumab) |
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
Curex offers the allergy immunity shot itself at home — at-home subcutaneous immunotherapy as one weekly self-administered injection at $129/month, building the same Treg-tolerance as clinic SCIT. The personalized serum is sterile-compounded to USP <797> standards and overseen by a board-certified allergist; the first dose and every dose change are supervised live over Zoom and a prescribed epinephrine auto-injector is confirmed on hand, so eligible maintenance patients skip the recurring clinic injections.
See if at-home shots are right for youFrequently asked questions
What are allergy immunity shots?
'Allergy immunity shots' is an informal name for subcutaneous immunotherapy (SCIT) — a 3-to-5-year course of allergen extract injections governed by the AAAAI/ACAAI/JCAAI Practice Parameter (Cox 2011 DOI 10.1016/j.jaci.2010.09.034). The clinically precise term is 'allergen immunotherapy' or 'tolerance induction.' The functional outcome feels like immunity (fewer or no symptoms on allergen exposure), but the immune mechanism is tolerance, not antibody-mediated immunity.
Do allergy shots build immunity like a vaccine?
No — the mechanism is the opposite of vaccine-induced immunity. Vaccines induce high-affinity IgG antibodies and T cell memory that attack a pathogen. Allergy shots induce regulatory T cells (Treg), IL-10, TGF-β, and IgG4 blocking antibodies that suppress the immune response to environmental allergens. Vaccines teach the immune system to attack; SCIT teaches it to stop overreacting. The end result feels similar (fewer symptoms on exposure) but the immunological pathway is reversed.
How long do allergy immunity shots last?
Per Cox 2011 PP3, the standard SCIT course is 3-5 years. Durham SR et al (NEJM 1999;341:468-475) documented 4 years of sustained remission after completing 3 years of grass SCIT. Some cohorts show 7-12+ years of durability. The post-treatment effect requires completing the full course — Tkacz 2021 (Curr Med Res Opin DOI 10.1080/03007995.2021.1903848) found only 43.9% of 103,207 MarketScan patients reached maintenance, and short-course discontinuation rarely produces durable tolerance.
Are allergy immunity shots permanent?
Not permanent in the absolute sense, but durable. Three to five years of SCIT produces approximately 4-12+ years of post-treatment remission. Some patients experience relapse 25-40% over 5 years post-discontinuation per the Cox/Cohn 2007 review. Re-starting protocols exist for patients who relapse. The closest 'permanent' analog is the pediatric PAT study (Jacobsen 2007 Allergy): 3-year SCIT in monosensitized children reduced asthma development at 10-year follow-up with OR 4.6 (95% CI 1.5-13.7) — a developmental protective effect that may be lifelong.
How do allergy immunity shots actually change the immune system?
Repeated sub-symptomatic allergen exposure shifts the immune response away from Th2 (IL-4, IL-5, IL-13 — the cytokines driving allergy) toward Treg cells producing IL-10 and TGF-β. Allergen-specific IgG4 'blocking' antibodies compete with IgE for the same allergen on mast cells. The downstream result: reduced histamine release, reduced eosinophil activation, reduced allergic inflammation on re-exposure. This is Treg tolerance, the same mechanism used in transplant tolerance and emerging cancer-immunotherapy approaches.
Are allergy immunity shots the same as SLIT drops or tablets — and can the shots be done at home?
Different route, same mechanism. SLIT (sublingual immunotherapy) is one at-home route: the four FDA-approved SLIT tablets (Grastek for timothy grass, Oralair for 5-grass mix, Ragwitek for short ragweed, Odactra for house dust mite) require daily dosing for 3-5 years, and off-label SLIT drops cover other allergens. But the injection route itself can now be done at home too — for eligible maintenance patients Curex delivers SCIT as one weekly self-administered shot for $129/month, a serum sterile-compounded to USP <797> standards with the first dose and every dose change supervised live over Zoom and a prescribed epinephrine auto-injector confirmed on hand. Both SCIT and SLIT operate through the same Treg-tolerance induction mechanism — the difference is sublingual mucosal exposure versus subcutaneous injection.
What conditions can allergy immunity shots treat?
Per Cox 2011 PP3, SCIT is indicated for allergic rhinitis (hay fever), allergic asthma with identifiable IgE-mediated triggers, allergic conjunctivitis, and Hymenoptera (bee, wasp, hornet) venom anaphylaxis. SCIT is NOT indicated for food allergy (the historical 1992 Oppenheimer peanut SCIT trial ended in a fatality; the field shifted to oral immunotherapy and Xolair), atopic dermatitis alone, chronic urticaria (Xolair has the FDA approval for that), or non-IgE-mediated symptoms.
What's the difference between allergy immunity shots and Xolair?
Xolair (omalizumab) is an anti-IgE biologic injection that binds free IgE in the bloodstream, preventing it from attaching to mast cells. It does not induce tolerance — when you stop Xolair, the effect ceases. SCIT (allergy immunity shots) induces durable tolerance via Treg cells and IgG4 blocking antibodies, with sustained post-treatment effect after completing the 3-5 year course. Xolair is FDA-approved for severe allergic asthma, chronic spontaneous urticaria, nasal polyps, and food-allergy reaction prevention (since February 2024). It is symptom control, not disease modification.
Related Articles
Allergy Shots: The Complete Patient Guide to SCIT | Curex
Allergy shots (SCIT) are the only FDA-recognized disease-modifying allergy treatment. Learn who qualifies, how they work, and what alternatives exist.
Read moreAllergy Vaccine Name – What Is the SCIT / SLIT Brand Called?
SCIT (allergy shots) has no brand name — extracts are custom-mixed. SLIT tablets have four FDA-approved brands: Grastek, Oralair, Ragwitek, Odactra.
Read moreAllergy Shot for Dog Allergies | Curex Human SCIT Guide
Yes, there is an allergy shot for humans allergic to dogs — but dog SCIT evidence is 'poor and conflicting.' 16.5% of patients may skip shots if Can f 5-monosensitized.
Read moreAllergy Desensitization: Which Treatment Type? | Curex
Allergy desensitization is active allergen-specific immunotherapy (SCIT or SLIT). Differs from passive immunotherapy and pharmacotherapy in mechanism.
Read moreAllergy Shots for Cats (Humans) | Curex SCIT Guide
Allergy shots for cats target Fel d 1 for HUMANS, not the pet. 23.9% quit conventional SCIT (Tkacz 2021). Curex delivers that SCIT at home, $129/mo.
Read moreAllergy Shots Name: SCIT Class Defined | Curex
The class name for allergy shots is subcutaneous immunotherapy (SCIT). No single brand name exists. Learn how SCIT extracts are named by source, unit labels, and how that differs from branded biologics.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.